The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on ...

Expanded indication for AKEEGA ® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with ...

Cancer charity highlights apparent ‘postcode lottery’ of testing and diagnoses across different regions seen in study ...

Decision making is evidence based and must be shielded from lobbying The NHS draft recommendation against routine prostate ...

Olympic legend Sir Chris Hoy says ‘we need more men to be diagnosed with prostate cancer early to stop them getting news I ...

Leading scientists are advocating for annual prostate cancer screening for men with BRCA1 and BRCA2 gene mutations. Experts at the London-based Institute of Cancer Research (ICR) state that the ...

Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...

Prostate cancer has overtaken breast cancer to become the most common form of the disease in the UK for the first time.

In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...